Yarrow Bioscience

YARW

市值 US$1.55億

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the closing of its previously announced underwritten public offering of 6,634,615 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 865,384 additional shares, at a public offering price per share of $26.00. Th.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of its previously announced underwritten public offering of 5,769,231 shares of its common stock at a public offering price per share of $26.00. The aggregate gross proceeds to Yarrow from the offering are expected to be approximately $150 million b.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Yarrow expects to grant the underwriter.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the completion of its merger with VYNE Therapeutics Inc. (“VYNE”), and the previously announced private financings totaling approximately $200 million. The combined company will operate as Yarrow Bioscience, Inc., with its shares expected to begin trading on th.

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) --  VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”), declared in connection with the terms and conditions of the Agreement and Plan of Merger and Reorganization, entered into on December 17, 2025, as amended (the “Merger Agreement”), with Yarrow Bioscience, Inc. (“Yarrow”) and Yellow Merger Sub Corp., was distributed, in cash, on July 23, 2026 to VYNE's stockholders of record as of July 22, 2026 (the “Record Date”), subject to the Nasdaq due bill procedures described below, based on their holdings as of the Record Date and during the Due Bill Period (as defined below) and prior to the reverse stock split.

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of VYNE's common stock at a ratio of 1-for-50 in connection with the anticipated closing of the proposed merger (the “Merger”) with Yarrow Bioscience, Inc. (“Yarrow”). The reverse stock split was previously approved by VYNE's stockholders at VYNE's special meeting in lieu of the annual meeting of stockholders held on July 16, 2026 (the “Special Meeting”).

Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share

MILWAUKEE , Dec. 18, 2025 /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Yarrow Bioscience. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating VYNE Therapeutics Inc. (NASDAQ: VYNE ) related to its merger with Yarrow Bioscience, Inc. Upon completion of the proposed transaction, VYNE shareholders are expected to own 3% of the combined company.